Home › Funds › Fidelity › Fidelity Advisor Biotechnology Fund
Fund family: Fidelity · Filed by FIDELITY ADVISOR SERIES VII (CIK 315700) · SEC series S000005321
Share classes and tickers: FBTAX (C000014519), FBTCX (C000014521), FBTIX (C000014523), FBTTX (C000014522), FIJYX (C000204999)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 480 with, 6 against, 0 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 5 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Fidelity’s manager page (1,165,189 ballot items across 406 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Fidelity | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 91.7% | 457 | 94.1% | 974,562 |
| Backed environmental and social shareholder proposals at US companies | n/a | 2 | 6.8% | 11,096 |
Each ballot item this fund voted is set against the votes of the other Fidelity funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Fidelity funds on 6 items (1.4% of the 424 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Fidelity funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Definium Therapeutics, Inc. | 2026-06-11 | To consider, and if deemed advisable, approve the amendment to the Definium Therapeutics, Inc. 2025 Equity Incentive Plan (the "2025 Equity Incentive Plan") to increase the number of common shares available for issuance under the 2025 Equity Incentive Plan by 5,000,000 common shares. | Against | FOR — 15 of 19 Fidelity funds | Against | Approved, 92.5% support |
| Tectonic Therapeutic, Inc. | 2026-06-08 | Election of Directors: Timothy A. Springer, Ph.D. | Withhold | FOR — 12 of 16 Fidelity funds | Against | Passed (calculated), 79.5% support |
| Rezolute, Inc. | 2025-11-19 | To elect the seven nominees to the Company's Board of Directors to serve until the 2027 Annual Meeting of Stockholders, until his or her successor is elected and shall have qualified or until his or her death, resignation, removal or disqualification: Erik Harris | Withhold | FOR — 12 of 19 Fidelity funds | Against | Passed (calculated), 81.2% support |
| Rezolute, Inc. | 2025-11-19 | To elect the seven nominees to the Company's Board of Directors to serve until the 2027 Annual Meeting of Stockholders, until his or her successor is elected and shall have qualified or until his or her death, resignation, removal or disqualification: Nerissa Kreher | Withhold | FOR — 12 of 19 Fidelity funds | Against | Passed (calculated), 76.6% support |
| uniQure N.V. | 2026-06-10 | Resolution to adopt the amendment to the Articles of Association to reflect Dutch large company regime. | For | AGAINST — 10 of 16 Fidelity funds | For | Approved, 74.5% support |
| Stoke Therapeutics, Inc. | 2026-06-03 | Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Julie Anne Smith | Withhold | FOR — 14 of 27 Fidelity funds | Against | Passed (calculated), 86.9% support |
Download all 6 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 77.0% of this fund’s 486 such votes could be given a sector; the other 112 (23.0%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 374 | 5 | 1.3% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 257 | 0 |
| Audit-related | 74 | 0 |
| Say-on-Pay | 73 | 0 |
| Capital Structure | 37 | 0 |
| Compensation | 30 | 1 |
| Corporate Governance | 25 | 3 |
| Shareholder Rights and Defenses | 2 | 0 |
| Environment or Climate | 1 | 1 |
| Other Social Issues | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| AbbVie Inc. | May 8, 2026 | $397M | 8 | 1 |
| Moderna, Inc. | May 6, 2026 | $145M | 5 | 0 |
| Gilead Sciences, Inc. | April 30, 2026 | $136M | 15 | 3 |
| argenx SE | November 18, 2025 | $99M | 1 | 0 |
| Spyre Therapeutics, Inc. | May 27, 2026 | $82M | 6 | 0 |
| Biogen Inc. | June 9, 2026 | $74M | 12 | 0 |
| Oruka Therapeutics, Inc. | June 2, 2026 | $73M | 4 | 0 |
| Amgen Inc. | May 19, 2026 | $70M | 15 | 1 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| June 30, 2026 | Inventiva SA | Authorize Capital Issuances for Use in Employee Stock Purchase Plans | For | Against |
500 ballot items at 72 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Fidelity Advisor Biotechnology Fund (FBTAX) voted at 72 shareholder meetings of 71 companies, on 500 ballot items in all. Where management made a recommendation, the fund followed it on 98.8% of the items and voted against it 6 times. Its most frequent area of disagreement was corporate governance (3 of its votes against management). It voted on 5 shareholder proposals. It voted FOR the board's own proposals less often than Fidelity's funds as a whole (91.7% against 94.1%). It voted differently from most Fidelity funds on 6 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Fidelity’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.